Biomedical papers - Ahead of Print

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | 10.5507/bp.2016.062

Chemokines in tumor proximal fluids

Jaromír Kotyza
Institute of Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilzen, Czech Republic

Chemokines are chemotactic cytokines produced by leukocytes and other types of cells including tumor cells. Their action is determined by the expression of cognate receptors and subsequent signaling in target cells, followed by the modulation of cytoskeletal proteins and the induction of other responses. In tumors, chemokines produced by neoplastic/stroma cells control the leukocyte infiltrate influencing tumor growth and progression. Tumor cells also express functional chemokine receptors responding to chemokine signals, promoting cell survival, proliferation and metastasis formation. Chemokines may be detected in serum of cancer patients, but due to the paracrine nature of these molecules, more significant concentrations are found in the tumor adjacent, non-vascular fluids, collectively called tumor proximal fluids. This review summarizes the expression of CC and CXC chemokines in these fluids, namely in interstitial fluid, pleural, ascitic, and cyst fluids, but also in urine, saliva, cerebrospinal fluid, cervical secretions and bronchoalveolar lavage fluid. Most comparative clinical studies reveal increased chemokine levels in high-grade tumor proximal fluids rather than in low-grade tumors and benign conditions, indicating shorter survival periods. The data confirm peritumoral fluid chemokines as sensitive diagnostic and prognostic markers, as well as offer support for chemokines and their receptors as potential targets for antitumor therapy.

Keywords: tumor proximal fluids, chemokine, chemokine receptors, metastasis

Received: September 13, 2016; Accepted: December 9, 2016; Prepublished online: January 6, 2017


References

  1. Yoshimura T. Discovery of IL-8/CXCL8 (the story from Frederick). Front Immunol 2015;6:278. [Epub ahead of print] doi:10.3389/fimmu.2015.00278 Go to original source... Go to PubMed...
  2. Majumdar R, Sixt M, Parent CA. New paradigms in the establishment and maintenance of gradients during directed cell migration. Curr Opin Cell Biol 2014;30:33-40. Go to original source... Go to PubMed...
  3. Maritzen R, Schachtner H, Legler DF. On the move: endocytic trafficking in cell migration. Cell Mol Life Sci 2015;72:2119-34. Go to original source... Go to PubMed...
  4. Bussmann J, Raz E. Chemokine-guided cell migration and motility in zebrafish development. EMBO J 2015;34(10):1309-18. Go to original source... Go to PubMed...
  5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74. Go to original source... Go to PubMed...
  6. Samadi AK, Bilsland A, Georgakilas AG, Amadei A, Amin A, Bishayee A, Azmi AS, Lokeshwar BL, Grue B, Panis C, Boosani CS, Poudyal D, Stafforini DM, Bhagta B, Niccolai E, Guha G, Rupasinghe HPV, Fujii H, Honoki K, Mehta K, Aquilano K, Lowe L, Hofseth LJ, Ricciardiello L, Ciriolo MR, Singh N, Whelan RL, Chaturvedi R, Ashraf SS, Kumara HMCS, Nowsheen S, Mohammed SI, Keith WN, Helferich WG, Yang X. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol 2015;35Suppl:151-84. Go to original source... Go to PubMed...
  7. Mukaida M, Sasaki S-I, Baba T. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm 2014. [Epub ahead of print] doi.org/10.1155/2014/170381
  8. Murakami T, Cardones AR, Hwang ST. Chemokine receptors and melanoma metastasis. J Dermatol Sci 2004;36(2):71-8. Go to original source... Go to PubMed...
  9. Yaacoub K, Pedeux R, Tarte K, Gillaudeux T. Role of the tumor microenvironment in regulating apoptosis and cancer progression. Cancer Lett 2016;378:150-9. Go to original source... Go to PubMed...
  10. Tas, F, Duranyildiz, D, Oguz, H, Camlica, H, Yasasever, V, Topuz, E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006;24(5):492-6. Go to original source... Go to PubMed...
  11. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, Nolen BM, Gorelik E. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006;102(2):244-51. Go to original source... Go to PubMed...
  12. Lippitz B. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14(6):e218-28. Go to original source... Go to PubMed...
  13. Sanmamed MF, Carranza-Rua O, Alfaro C, Onate C, Martin-Algarra S, Perez G, Landazuri SF, Gonzales A, Gross S, Rodrigez I, Munoz-Calleja C, Rodrigez-Ruiz M, Sangro B, Lopez-Picazo JM, Rizzo M, Mazzolini G, Pascual JI, Andueza MP, Perez-Garcia JL, Melero I. Serum interleukin-8 reflects tumor burden and treatment response across malignances of multiple tissue origins. Clin Cancer Res 2014;20(22):5697-707. Go to original source... Go to PubMed...
  14. Alexandrakis MG, Coulocheri SA, Bouros D, Eliopoulos GD. Evaluation of ferritin, interleukin-6, interleukin-8 and tumor necrosis factor alpha in the differentiation of exudates and transudates in pleural effusions. Anticancer Res 1999;19(4C):3607-12. Go to PubMed...
  15. Ivarsson K, Runesson E, Sundtfeldt K, Haeger M, Hedin L, Janson PO, Mats Brannstrom M. The chemotactic cytokine interleukin-8 - a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncology 1998;71(3):420-3. Go to original source... Go to PubMed...
  16. Lee HL, Eom H-S, Yun T, Kim H-J, Park W-S, Nam B-H, Moon-Woo S, Lee D-H, Kong S-Y. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma. Cytokine 2008;43(1):71-5. Go to original source... Go to PubMed...
  17. Gentile LF, Cuenca AG, Vanzant EL, Efron PA, McKinley B, Moore F, Moldawer LL. Is there value in plasma cytokine measurments in patients with severe trauma and sepsis? Methods 2013;61(1):3-9. Go to original source... Go to PubMed...
  18. Kotyza J. Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: its diagnostic and prognostic value. A Review. Int J Biol Markers 2012;27(3):169-78. Go to original source... Go to PubMed...
  19. Kotyza , Havel D, Vrzalová J, Kulda V, Pešek M. Diagnostic and prognostic significance of inflammatory markers in lung cancer associated pleural effusions. Int J Biol Markers 2010;25(1):12-20. Go to PubMed...
  20. Pavlou MP, Diamandis EP. The cancer cell secretome: A good source for discovering biomarkers? J Proteomics 2010;73(10):1896-906. Go to original source... Go to PubMed...
  21. Dennebaum R. Extravascular body fluids. In: Thomas L, editor. Clinical laboratory diagnostics, Frankfurt, Germany: TH-Books Verlagsgesellschaft mbH; 1998. p1327-75.
  22. Schaaij-Visser TBM, de Wit M, Lam SW, Jimenez CR. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Bioch Biophys Acta 2013;1834:2242-58.
  23. Celis JE, Gromov P, Cabezon T, Moreira JMA, Ambartsumian N, Sandelin K, Rank F, Gromova I. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment. Mol Cellular Proteomics 2004;3:327-44. Go to original source...
  24. Bendrik C, Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol 2009;182(1):371-78. Go to original source... Go to PubMed...
  25. Svensson S, Abrahamsson A, Rodriguez GV, Olsson A_K, Jensen L, Cao Y, Dabrosin C. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clin Cancer Res 2015; 21(16):3794-805. Go to original source... Go to PubMed...
  26. Portnow J, Badie B, Liu X, Frankel P, Mi S, Chen M. A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent. J Neuroconcol 2014;118:169-77. Go to original source... Go to PubMed...
  27. Olopade OI, Ultmann JE. Malignant effusions. CA Cancer J Clin 1991;41(3):166-79. Go to original source... Go to PubMed...
  28. Antony VB, Goodbey SW, Kunkel SL, Hott JW, Hartman DL, Burdick MD, Strieter RM. Recruitment of inflammatory cells to the pleural space. Chemotactic cytokines, IL-8, and monocyte chemotactid peptide-1 in human pleural fluids. J Immunol 1993;151(12):7216-23. Go to PubMed...
  29. Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassilou S, Karatza M, Zhou Z, Joo M, Blackwell TS, Roussos C, Graf D, Kalomenidis I. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Nat Cancer Inst 2008;100(20):1464-76. Go to original source... Go to PubMed...
  30. Quin X-J, Shi H-Z, Deng J-M, Liang Q-L, Jiang J, Ye Z-J. CCL22 recruits CD4-positive CD25-popositive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009;15(7):2231-7. Go to original source... Go to PubMed...
  31. Zaki SM, Ashour L. Pleural fluid IL-8 as an inflammatory mediator for discriminating transudates and exudates. Egypt J Immunol 2007;14(2):83-92. Go to PubMed...
  32. Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncol Res 1999;11(4):187-94. Go to PubMed...
  33. Economidou F, Antoniou KM, Soufla G, Lasithiotaki I, Karagiannis K, Lymbouridou R, Proklou A, Spandidos DA, Siafakas NM. Role of VEGF-stromal cell-derived factor-1alpha/CXCL12 in pleural effusion of lung cancer. J Recept Signal Transduct Res 2010;30(3):154-60. Go to original source... Go to PubMed...
  34. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokine and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002;8(4):1108-14. Go to PubMed...
  35. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhassel B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J. Identification of biologically active chemokine Isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002;277(27):24584-93. Go to original source... Go to PubMed...
  36. Matte I, Lane D, Laplante C, Rancourt C, Piché A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2012;2(5):566-80. Go to PubMed...
  37. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006;55:1185-97. Go to original source... Go to PubMed...
  38. Radke J, Schmidt D, Bohme M, Schmidt U, Weise W, Morenz J. Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd 1996;56(2):83-7. Go to original source... Go to PubMed...
  39. Nowak M, Glowacka E, Szoakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J. Proinflammatory and immunosupressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010;31(3):375-83. Go to PubMed...
  40. Abe T, Sakamoto K, Kamohara H, Hirano Y, Kuwahara N, Ogawa M. Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int I Cancer 1997;74(3):245-50. Go to original source... Go to PubMed...
  41. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10(1):33-41. Go to original source... Go to PubMed...
  42. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clinical Exp Metastasis 2002;19(2):135-44. Go to original source... Go to PubMed...
  43. Wertel I, Polak G, Tarkowski R, Kotarska M. SDF-1alpha/CXCL12 and dendritic cells in ovarian cancer microenvironment. Ginekol Polski 2011;82(6):421-25. Go to PubMed...
  44. Obermajer N, Muthuswamy R, Odunsi K., Edwards RP, Kalinski P. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011;71(24):7463-70. Go to original source... Go to PubMed...
  45. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 2006;66(7):2181-7. Go to original source... Go to PubMed...
  46. Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H, Wu M, Zhou W. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 2008;5(5):373-8. Go to original source... Go to PubMed...
  47. Kuratsu J, Yoshizato K, YoshimuraT, Leonard EJ, Takeshima H, Ushio Y. Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst 1993;85(22):1836-9. Go to original source... Go to PubMed...
  48. Van Meir E, Ceska M, Effenberger F, Waltz A, Grouzmann E, Desbaillets I, Frei K, Fontana A, de Tribolet N. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res 1992;52(16):4297-305. Go to PubMed...
  49. Fasciani A, D'Ambrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 2001;75(6):1218-21. Go to original source... Go to PubMed...
  50. Darai E, Detechev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Human Reproduction 2003;18(8):1681-5. Go to original source... Go to PubMed...
  51. Yigit R, Massuger LF, Zusterzeel PL, Pots J, Figdor CG, Torensma R. Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. Int J Gynecol Cancer 2011;21(7):1241-7. Go to original source... Go to PubMed...
  52. Maker AV, Katabi N, Quin L-X, Klimstra DS, Schattner M, Brennan MF, Jarnagin WR, Allen PJ. Cyst fluid interleukin-1b(IL1b) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2011;17(6):1502-8. Go to original source... Go to PubMed...
  53. Bussom S, Saif MW. Itraductal papillary mucinous neoplasia (IPMN). In: Highlights from "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010; J Pancreas 2010;11(2):131-4.
  54. Uchikawa C, Shinozaki T, Nakajima T, Tkagishi K. Cytokine synthesis by chondroblastoma: relation to local inflammation. J Orthopaedic Surgery 2009;17(1):56-61. Go to original source... Go to PubMed...
  55. Kolokythas A, Karas M, Sarna T, Flick W, Miloro M. Does cytokine profiling of aspirate from jaw cysts and tumors have a role in diagnosis? J Oral Maxillofac Surg 2012;70(5):1070-80. Go to original source... Go to PubMed...
  56. Reid CN, Stevenson M, Abogunrin F, Ruddock MY, Emmert-Streib F, Lamont JV, Williamson KE. Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat. PLoS ONE 2012; 7(12). [Epub ahead of print] doi: 10.1371/journal.pone.0053354 Go to original source... Go to PubMed...
  57. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One 2012; 7(12). [Epub ahead of print] doi: 10.1371/journal.pone.0037797 Go to original source...
  58. Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, Alcaraz A, Giacoia EG, Goodison S, Rosser CJ. Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urology 2013. [Epub ahead of print] doi: 10.1186/1471-2490-13-42 Go to original source...
  59. Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E, Ogawa O. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res 2008;14(9):2579-87. Go to original source... Go to PubMed...
  60. Urquidi V, Chang M, Dai Y, Kim J, Wolfson ED, Goodison S, Rosser CJ. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol 2012. [Epub ahead of print] doi:10.1186/1471-2490-12-12 Go to original source... Go to PubMed...
  61. Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003;62(1):162-6. Go to original source... Go to PubMed...
  62. Kocak H, Oner-Iyidogan Y, Kocak T, Oner P. Determination and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Bioch 2004;37(8):673-8. Go to original source... Go to PubMed...
  63. Margel D, Pesvner-Fischer M, Baniel J, Yossepowitch O, Cohen IR. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urology 2011;59(1):113-9. Go to original source... Go to PubMed...
  64. Rosser CJ, Dai Y, Miyake M, Zhang G, Goodison S. Simultaneous multi-analyte urinary protein assay for bladder cancer detection. BMC Biotechnology 2014; [Epub ahead of print] doi:10.1186/1472-6750-14-24 Go to original source... Go to PubMed...
  65. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS ONE 2012;7. [Epub ahead of print] doi: 10.1371/journal.pone.0047469 Go to original source...
  66. Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS, Lokeshwar VB. Differential expression of stroma derived factor-1 isoforms in bladder cancer. J Urol 2014;191(6):1899-905. Go to original source... Go to PubMed...
  67. Spielmann N, Wong DT. Saliva: diagnostics and therapeutic perspectives. Oral Dis 2011;17(4):345-54. Go to original source... Go to PubMed...
  68. St John MA, Li Y, Zhou X, Denny P, Ho C-M, Montemagno C, Shi W, Qi F, Wu B, DDS, Sinha U, Jordan R, Wolinsky L, Park N-H, Liu H, Abemayor E, Wong DTW. Interleukin 6 and Interleukin 8 as Potential Biomarkers for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg 2004;130(8):929-35. Go to original source... Go to PubMed...
  69. Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park N-H, Wong DT. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004;10(24): 8442-50. Go to original source... Go to PubMed...
  70. Elashoff D, Zhou H, Reiss J, Wang J, Henson B, Hu S, Arellano M, Sinha U, Le A, Messadi D, Wang M, Nabili V, Lingen M, Morris D, Randolph T, Feng Z, Akin D, Kastratovic DA, Chia D, Abenmayor E, Wong DT. Pre-validation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev 2012;21(4):664-72. Go to original source... Go to PubMed...
  71. Rajkumar K, Nandhini G, Ramya R, Rajashree P, Kumar AR, Anandan SN. Validation of diagnostic utility of salivary interleukin 8 in the differentiation of potentially malignant oral lesions and oral squamous cell carcinoma in a region with high endemicity. Oral Surg Oral Med Oral Pathol Radiol 2014;118(3):309-19. Go to original source... Go to PubMed...
  72. Cheng Y-SL, Jordan L, Gorugantula LM, Schneiderman E, Chen H-S, Rees T. Salivary interleukin-6 and -8 in patients with oral cancer and patients with chronic oral inflammatory diseases. J Periodontology 2014; 85(7): 956-65. Go to original source... Go to PubMed...
  73. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29(1):42-5. Go to original source... Go to PubMed...
  74. Punyani SR, Sathawane RS. Salivary level of interleukin-8 in oral precancer and oral squamous cell carcinoma. Clin Oral Invest 2013;17(2):517-24. Go to original source... Go to PubMed...
  75. Korostoff A, Reder L, Masood R, Sinha UK. The role of salivary cytokine biomarkers in tongue cancer invsion and mortality. Oral Oncol 2011;47(4):282-7. Go to original source... Go to PubMed...
  76. Michiels K, Schutyser E, Conings R, Lenaerts JP, Put W, Nuyts S, Delaere P, Jacobs R, Struyf S, Proost P, Van Damme J. Carcinoma cell-derived chemokines and their presence in oral fluid. Eur J Oral Sci 2009;117(4):362-8. Go to original source... Go to PubMed...
  77. Prasad G, McCullough M. Chemokines and cytokines as salivary biomarkers for the early diagnosis of oral cancer. Int J Dentistry 2013. [Epub ahead of print] doi: 10.1155/2013/813756 Go to original source...
  78. Sahingur SE, Yeudall WA. Chemokine function in periodontal disease and oral cavity cancer. Frontiers Immunol 2015;6. [Epub ahead of print] doi: 10.3389/ fimmu.2015.00214 Go to original source...
  79. Liu G-X, Lan J, Sun Y, Hu Y-J, Jiang G-S.. Expression of the chemokine CCL28 in pleomorphic adenoma and adenolymphoma fot he human salivary glands. Exp Ther Med 2012;4(1):65-9. Go to PubMed...
  80. Felgenhauer K. Laboratory diagnosis of neurological diseases. In: Thomas L, editor. Clinical laboratory diagnostics. Frankfurt, Germany: TH-Books Verlagsgesellschaft mbH; 1998: p.1308-26.
  81. Si M-Y, Fan Z-C, Li Y-Z, Chang X-L, Xie Q-D, Jiao X-Y. The prognostic significance of serum and serebrospinal fluid MMP-9, CCL-2 and sVCAM in leukemia CNS metastasis. J Neurooncol 2015;122(2):229-44. Go to original source... Go to PubMed...
  82. Protas PT, Holownia A, Muszynska-Roslan K, Wielgat P, Krawczuk-Rybak M, Braszuko JJ. Cerebrospinal fluid IL-6, TNF-alpha and MCP-1 in children with acute lymphoblastic leukaemia during chemotherapy. Neuropediatrics 2011;42(6):254-6. Go to original source... Go to PubMed...
  83. Lok E, Chung AS Swanson KD, Wong ET. Melanoma brain metastasis globaly reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. Melanoma Res 2014;24(2):120-30. Go to original source... Go to PubMed...
  84. Brandsma D, Taphoorn MJ, de Jager W, Bonfrer H, Algra A, Reijneveld JC, Boogerd W, Korse T, Verbeek MM, Rijkers G, Voest EE. Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases. Neurology 2006;66(2):243-6. Go to original source... Go to PubMed...
  85. Brandsma D, Voest EE, de Jager W, Bonfrer H, Algra A, Boogerd W, Korse T, Reijneveld JC, Verbeek MM, Rijkers G, Taphoorn MJB. CSF protein profiling using Multiplex Immuno-assay. J Neurol 2006;253(9):1177-84. Go to original source... Go to PubMed...
  86. Lieberman JA, Moscicki A-B, Sumerel JL, Ma Y, Scott ME. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol 2008;15(1):49-54. Go to original source... Go to PubMed...
  87. Koshiol J, Sklavos M, Wentzensen N, Kemp T, Schiffman M, Dunn ST, Wang SS, Walker JL, Safaeian M, Zuna RE, Hildesheim A, Pfeiffer RM, Pinto LA. Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodological study. Int J Cancer 2014;134(2):411-25. Go to original source... Go to PubMed...
  88. Tavarez-Murta BM, de Resende AD, Cunha FQ, Murta EFC. Local profile of cytokines and nitric oxide in patients with bacterial vaginosis and cervical intraepithelial neoplasia. Eur J Obstetrics Gynecol Reprod Biol 2008;138(1):93-9. Go to original source...
  89. Tjiong MY, Van der Vange N, ten Kate FJW, Tjong-A-Hung SP, ter Schegget J, Burger MP, Out TA. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecologic Oncology 1999;73(2):285-91. Go to original source... Go to PubMed...
  90. Plymoth A, Lofdahl C-G, Ekberg-Jansson A, Dahlback M, Lindberg H, Fehniger TE, Marko-Varga G. Human bronchoalveolar lavage: Biofluid analysis with special emphasis on sample preparation. Proteomics 2003;3(6):962-72. Go to original source... Go to PubMed...
  91. Chen L, Li Q, Zhou X-D, Shi Y, Yang L, Xu S_L, Chen C, Cui Y-H, Zhang X, Bian X-W. Increased pro-angiogenic factors, infiltrating neutrophils and CD 163+ macrophages in bronchoalveolar lavage fluid from lung cancer patients. Int Immunopharmacol 2014;20(1):74-80. Go to original source... Go to PubMed...
  92. Crohns M, Saarelainen S, Laine S, Poussa T, Alho H, Kellokumpu-Lehtinen P. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - association of interleukin-8 and VEGF with survival. Cytokine 2010;50(1):30-6. Go to original source... Go to PubMed...
  93. Hayes SA, Haefliger S, Harris B, Pavlakis N, Clarke SJ, Molloy MP, Howell VM. Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. J Breath Res 2016;10.[Epub ahead of print] doi:10.1088/1752-7155/10/3/034001 Go to original source... Go to PubMed...
  94. Fang WB, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C, Cheng N. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget 2016 Jun 7.[Epub ahead of print] doi: 10.18632/oncotarget.9885 Go to original source... Go to PubMed...
  95. Zlotnik A. Chemokines in neoplastic progression. Seminars Cancer Biol 2004;14:181-5. Go to original source... Go to PubMed...
  96. Yang Q, Zhang F, Ding Y,, Huang J, Chen S,, Wu Q, Wang Z, Wang Z, Chen C. Antitumor activity of the recombinant polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. Br J Cancer 2014;110(5):1288-97. Go to original source... Go to PubMed...
  97. Shepard JB, Wilkinson RA, Starkey JR, Teintze M. Novel guanidine-substituted compounds bind to CXCR4 and inhibit breast cancer metastasis. Anticancer Drugs 2014;25(1):8-16. Go to original source... Go to PubMed...
  98. Liu W, Wang Y, Wang H, Wang A. Anticancer effects of chemokine receptor 4(CXCR4) gene silenced by CXCR4-siRNA in nude mice model of ovarian cancer. Cell Biochem Biophys 2014;70(3):1893-900. Go to original source... Go to PubMed...
  99. Chatterjee S, Azad BB, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res 2014;124:31-82. Go to original source... Go to PubMed...
  100. Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievments and challenges. Frontiers Immunol 2015 Jan 30.[Epub ahead of print] doi: 10. 3389/fimmu.2015.00012 Go to original source...
  101. Azad BB, Chatterjee S, Lesniak WG, Lisok A, Pullambhatla M, Bhujwalla ZM, Pomper MG, Nimmagadda S. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Oncotarget 2016;7(11):12344-58. Go to PubMed...
  102. Meuris F, Gaudin F, Akinin ML, Hémon P, Berrebi D, Bachelerie F. Symptomatic improvement in human papilloma-induced epithelial neoplasia by specific targeting of the CXCR4 chemokine receptor. J Invest Dermatol 2016;136(2):473-80. Go to original source... Go to PubMed...
  103. Xu C, Zhao H, Chen H, Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther 2015;9:4953-64. Go to PubMed...